Importantly, protein binders are not drugs. Designing a high-affinity binder is just the first step in the process of developing a drug-like molecule. Even designing a drug itself is just one phase out of the many required to establish that a drug is safe and effective before making it available to people.

However, this establishes a strong foundation to work from, and we are building on it by teaching Claude to run the entire development process end-to-end for every major type of drug molecule—from antibodies to small molecules.